01 Integration of IoT Connectivity with Drug Delivery Systems The connected drug delivery devices market analysis shows shift towards the integration of IoT connectivity with drug delivery systems for real-time device and medication monitoring. Connected devices can transmit information such as dosage, administration time, device status, and usage patterns to mobile applications or digital healthcare platforms. This integration is improving data visibility and enabling healthcare professionals to monitor treatment information remotely.
02 Shift toward Connected Autoinjectors and Smart Pens The connected drug delivery devices market is witnessing growth in connected autoinjectors and smart insulin pens equipped with digital sensors, connectivity features, and dose-tracking capabilities. These devices can record injection timing, dosage information, and device usage while transferring data to connected applications. The integration of digital features is improving medication tracking and supporting more structured management of injectable therapies.
01 Supply chain disruptions are expected to have a high impact on the connected drug delivery devices market share due to dependence on sensors, microcontrollers, semiconductors, batteries, connectivity modules, electronic components, and specialized medical-device manufacturing and distribution networks. The market is expected to follow a U-shaped recovery, as shortages of electronic components, sensor production delays, higher component costs, and medical-device logistics constraints can prolong supply interruptions before manufacturing and inventory levels stabilize. The market is expected to grow at a CAGR of 16.69%, but supply chain constraints could approximately lower this by 1.5 percentage points, resulting in short-term growth of around 15.19%. As supply conditions normalize through improved availability of semiconductors and sensors, stabilized component costs, expanded manufacturing capacity, and smoother medical-device logistics, connected drug delivery devices market growth is expected to gradually return to 16.69%.
01 The connected drug delivery devices market forecasts strategic investment activity driven by smart drug delivery platform development, wearable injector expansion, medication adherence monitoring, connected device integration, digital health capabilities, and manufacturing scale-up.
02 Key Investments and Funding Activities in Connected Drug Delivery Devices Market, 2025–2026 Company Value (USD) Details ViCentra USD 98 Million In January 2026, ViCentra closed a USD 13 million extension to its Series D financing, bringing the total Series D funding to USD 98 million. The funding is supporting manufacturing scale-up, commercial expansion, and planned U.S. market access for its Kaleido insulin patch pump, a connected drug delivery device. Daré Bioscience USD 4 Million In October 2025, Daré Bioscience received a USD 4 million non-dilutive funding installment under a grant agreement supporting development of its DARE-IDDS intelligent drug delivery system. The installment brought total funding received under the commitment to approximately USD 41.8 million, supporting development of a programmable drug delivery device.
01 Need for Medication Adherence Monitoring and Demand for Real-Time Dose Tracking Drives Market The need for medication adherence monitoring is driving demand for connected devices that help patients follow prescribed treatment schedules. Digital drug delivery systems can record dosing activity and provide reminders when scheduled doses are missed. Connected data can also help healthcare providers monitor treatment use and identify adherence gaps. This focus on better medication management is supporting adoption of connected drug delivery devices.The demand for real-time dose tracking is increasing the use of connected drug delivery devices that capture and share dosing information. Integration with remote patient monitoring (RPM) systems allows healthcare providers to receive medication-use data without requiring frequent in-person visits. Real-time information can support timely follow-up and improve visibility into treatment patterns. This growing need for connected monitoring supports connected drug delivery devices market growth.
01 Difficulty in Maintaining Patient Engagement and Inconsistent Data Synchronization Across Devices Restrains Market Expansion Difficulty in maintaining patient engagement can limit the effective use of connected drug delivery devices over time. Patients may stop using companion apps, ignore reminders, or lose interest in tracking their medication after initial adoption. Low engagement can reduce the effectiveness of medication adherence monitoring and remote patient monitoring (RPM) features. This can limit the long-term value of digital drug delivery solutions and restrain market growth.Inconsistent data synchronization can affect the reliability of information collected from connected drug delivery devices. Delays or errors in transferring dose records between devices, mobile applications, and cloud platforms can result in incomplete or inaccurate medication data. Such issues can reduce the usefulness of real-time dose tracking for patients and healthcare providers.
01 Expansion of Connected Drug Delivery in Chronic Disease Management and Integration with Internet of Medical Things (IoMT) Offers Growth Opportunities The need for long-term treatment is creating opportunities for connected drug delivery device manufacturers to serve patients managing diabetes, asthma, and cardiovascular conditions. Digital drug delivery devices can support medication adherence through dose tracking, reminders, and connected monitoring features.The growing adoption of the Internet of Medical Things (IoMT) is creating opportunities for connected drug delivery device manufacturers to link smart injectors, inhalers, pumps, and other devices with healthcare networks. Companies such as Medtronic and Becton, Dickinson and Company can benefit by developing IoMT-enabled drug delivery solutions, creating revenue through connected devices, software platforms, and data-enabled services.
01 Limited Standardized Outcomes and Complex Interoperability with Healthcare Systems Hinders Market Growth Manufacturers face difficulties generating robust evidence that connected drug delivery devices improve medication adherence, clinical outcomes, or healthcare efficiency. Limited standardized outcome measures and economic evidence can make payer and provider acceptance more difficult, increasing evidence-generation costs and slowing commercial expansion.Connected drug delivery devices must exchange data with EHRs, healthcare apps, and other digital systems, but differences in data standards and system architectures can require customized interfaces and additional testing. These integration requirements increase development and implementation costs, delay deployment, and make expansion across healthcare systems more complex.